Trial reportKorean journal of anesthesiology2025
Effect of low-dose volatile anesthetics on intraoperative neurophysiological monitoring during anesthesia with remimazolam.
Trial report in Korean journal of anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intraoperative neurophysiological monitoring (IONM) in neurosurgery: A critical appraisal of established practices, ongoing controversies, and future trajectories.Journal of anesthesia and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemimazolam is a novel short-acting benzodiazepine. We investigated the effects of low doses of volatile anesthetic agents on motor evoked potentials (MEPs) and somatosensory evoked potentials (SSEPs) during remimazolam-remifentanil anesthesia.
methodsThirty-nine patients undergoing cervical spine surgery were randomly assigned to either the sevoflurane (n = 20) or desflurane (n = 19) groups. Volatile anesthetic agents were administered at 0.3, 0.6, and 0.8 minimum alveolar concentrations (MACs) during remimazolam-remifentanil anesthesia. Significant changes were considered as more than 50% amplitude suppression and more than 10% latency increase from baseline values. The primary outcome was MEP amplitude change. Secondary outcomes included MEP latency, SSEP amplitude and latency, and group comparisons.
resultsThe MEP amplitudes were slightly reduced at 0.3 MAC; however, a suppression of more than 50% from baseline values at 0.3 MAC, particularly in the upper limbs, was observed in a notable proportion of participants; 30.0% and 47.4% in the sevoflurane and desflurane groups, respectively. The corresponding percentages for the lower limbs were 15.0% and 15.8%, respectively. MEP amplitude suppression was more than 50% in the majority of participants at 0.6 and 0.8 MAC. No significant difference was observed between the groups. SSEPs exhibited no significant amplitude suppression or latency prolongation across all MAC levels.
conclusionsNotable MEP amplitude suppression was observed in many patients when 0.3 MAC volatile anesthetics were used as adjuncts. Therefore, even low doses of volatile anesthetics must be added cautiously to remimazolam-based anesthesia to prevent confounding. The SSEPs were relatively preserved, regardless of MAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.